Lodo Therapeutics, a biotechnology company, completed the acquisition of Conifer Point Pharmaceuticals, a computational chemistry services provider. Financial terms were not disclosed. "We are delighted to join forces with Lodo, whose commitment to applying informatics, genomics and synthetic biology to reinvent natural product drug discovery is fully aligned with our vision. We see Lodo as well situated to extend the full potential of our unique technology to the domain of natural product therapeutics. I look forward to serving as a consultant to help the Lodo team make optimal use of these powerful tools," John Kulp III, Conifer Point CEO.